Relay Therapeutics, Inc.

Listed Company

RLAYCIK 0001812364NasdaqLarge AcceleratedBiological Products, (No Diagnostic Substances)DelawareFY ends Dec 31

Period

FY 2025

Revenue

$15.36M

Net Income

$-276.48M

Total Assets

$621.33M

Equity

$567.06M

Shares Out

191.59M

Op. Cash Flow

$-235.46M

RLAY$19.91+445.34% · past yearDBEQ Basic

Daily closing prices

Business

Relay Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision medicines for cancer and genetic disease using its Dynamo platform and Motion-Based Drug Design approach. The company's lead candidate, zovegalisib, is an allosteric PI3Kα inhibitor in Phase 3 development for hormone receptor positive breast cancer and Phase 1/2 development for vascular anomalies; additional programs target NRAS-mutated solid tumors and Fabry disease. Relay is advancing its pipeline through internal development and strategic partnerships, including a collaboration with Pfizer and a licensing agreement with Elevar for its FGFR2 inhibitor program.

Summary from 10-K filed 2026-02-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
License and other revenue	15	10	26	1	3
Total revenue	15	10	26	1	3
Research and development expenses	261	319	330	246	173
Change in fair value of contingent consideration liability	—	−13	−6	−12	3
General and administrative expenses	57	77	75	66	57
Total operating expenses	318	382	399	301	368
Loss from operations	−303	−372	−373	−299	−365
Interest income	27	35	31	9	830,000
Other (expense) income	−776,000	14,000	−18,000	−20,000	−4,000
Total other income, net	26	35	31	9	826,000
Net loss	−276	−338	−342	−291	−364
Net loss per share, basic	−1.61	−2.36	−2.79	−2.59	−3.82
Net loss per share, diluted	−1.61	−2.36	−2.79	−2.59	−3.82
Weighted average shares of common stock, basic	172	143	123	112	95
Weighted average shares of common stock, diluted	172	143	123	112	95
Unrealized holding gain (loss)	2	−795,000	10	−9	−1
Total other comprehensive income (loss)	2	−795,000	10	−9	−1
Total comprehensive loss	−275	−339	−332	−300	−365

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	84	124	144	152	280
Investments	471	657	606	847	678
Prepaid expenses	18	17	17	12	11
Other current assets	6	11	3	3	2
Total current assets	578	809	770	1,020	976
Property and equipment, net	2	6	11	12	7
Operating lease assets	40	52	58	64	21
Restricted cash	1	2	3	3	3
Intangible asset	0	2	2	—	—
Total assets	621	871	844	1,100	1,008
Accounts payable	8	14	9	11	8
Accrued expenses	14	21	15	23	14
Operating lease liabilities	4	6	5	4	2
Deferred revenue	—	8	—	—	—
Other current liabilities	463,000	2	1	26	396,000
Total current liabilities	26	51	30	64	24
Operating lease liabilities, net of current portion	29	43	49	53	21
Total liabilities	54	94	92	150	111
Commitments and contingencies (Note 11)	—	—	—	—	—
Common stock, $0.001 par value; 300,000,000 shares authorized as of December 31, 2024 and December 31, 2024; 173,868,949 and 167,755,715 shares issued and outstanding as of December 31, 2025 and December 31, 2024,respectively	168,000	168,000	127,000	121,000	109,000
Additional paid-in capital	2,581	2,517	2,153	2,019	1,667
Accumulated other comprehensive loss	733,000	−991,000	−196,000	−10	−1
Accumulated deficit	−2,000	−1,738	−1,401	−1,059	−768
Total stockholders' equity	567	778	752	950	898
Total liabilities and stockholders' equity	621	871	844	1,100	1,008

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation expense	4	5	5	4	4
Stock compensation expense	62	94	86	56	48
Impairment of intangible asset	2	—	—	—	—
Net realized gain on sale of investments	—	−101,000	—	—	—
Loss on disposal of property and equipment	1	—	—	—	—
Net amortization of premiums and discounts on investments	−5	−12	−11	1	2
Accounts receivable	—	—	306,000	97,000	75
Contract asset	—	—	5	−376,000	3
Prepaid expenses and other current assets	2	−5	−5	−2	−3
Operating lease assets and liabilities, net	−4	1	2	−8	277,000
Accounts payable and accrued expenses	−11	10	−10	11	—
Deferred revenue	−8	8	—	−248,000	—
Other liabilities	−2	786,000	−25	11	15
Net cash used in operating activities	−235	−249	−300	−229	−74
Purchases of property and equipment	−410,000	−2	−4	−9	−3
Purchases of investments	−123	−651	−386	−535	−981
Proceeds from maturities and sales of investments	316	612	647	356	530
Net cash provided by (used in) investing activities	193	−41	258	−189	−480
Proceeds from issuance of common stock through Private Placement, net	—	30	—	—	—
Proceeds from issuance of common stock via at-the-market offerings, net	—	18	30	—	—
Proceeds from issuance of common stock through follow-on offering, net	—	218	—	285	382
Proceeds from issuance of common stock through exercise of stock options	524,000	3	2	3	—
Proceeds from issuance of common stock via employee stock purchase plan	1	1	2	2	—
Net cash provided by financing activities	2	270	35	290	388
Net decrease in cash, cash equivalents, and restricted cash	−41	−20	−8	−128	−166
Periodic change in additions of property and equipment within current liabilities	−35,000	−2	410,000	159,000	—
Periodic change in costs to obtain license agreement within current liabilities	−3	3	—	—	—
Operating lease assets obtained in exchange for operating lease liabilities	7	—	—	47	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Relay Therapeutics, Inc.'s CIK number?

Relay Therapeutics, Inc.'s SEC CIK number is 0001812364 (1812364). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Relay Therapeutics, Inc.'s SEC filings?

All of Relay Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Relay Therapeutics, Inc. last report earnings?

Relay Therapeutics, Inc. (RLAY) most recently filed an earnings 8-K with the SEC on May 5, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-206398). This is Relay Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Relay Therapeutics, Inc.'s most recent earnings 8-K?

Relay Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 5, 2026 under accession 0001193125-26-206398. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Relay Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →